Filing Details

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

       

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

 (Name of Issuer)

 

 (Title of Class of Securities)

 

 (CUSIP Number)

 

 (Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☑         Rule 13d-1(b)

 

☐          Rule 13d-1(c)

 

☐          Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Continued on following pages

Page 1 of 10 Pages

Exhibit Index: Page 9

CUSIP No. 22663K107

Page 2 of  10 Pages

 

¹ Based on 53,810,476 Shares (as defined herein) outstanding as of November 9, 2022, as reported in the Issuer’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2022 filed with the Securities and Exchange Commission (the “SEC”) on November 14, 2022.

 

 

Item 1(a).

Crinetics Pharmaceuticals, Inc.

Item 1(b).

10222 Barnes Canyon, Bldg. #2

San Diego, CA 92121

This initial filing is being jointly filed by Braidwell LP, Braidwell Management LLC, Alexander Karnal and Brian Kreiter (the “Reporting Persons”).

The business address of each Reporting Person is:

2200 Atlantic St

4^th Floor

Stamford, CT 06902

Braidwell LP is a limited partnership organized under the laws of the State of Delaware.

Braidwell Management LLC is a limited liability company organized under the laws of the State of Delaware. Alexander Karnal and Brian Kreiter are both citizens of the United States of America.

Item 2(d).

Common Stock, par value $0.001 per share (the “Shares”)

Item 2(e).

22663K107

Item 3.

(e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E)

(g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)

Item 4.

Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 3,469,674 Shares, which are directly owned by Braidwell Partners Master Fund LP.

 

Each Reporting Person may be deemed to beneficially own 6.45% of the Shares, which is calculated based on 53,810,476 Shares outstanding as of November 9, 2022, as reported in the Issuer’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2022 filed with the SEC on November 14, 2022.

Item 4(c)

 

 

Item 5.

n/a

Item 6.

n/a

Item 7.

The information in Item 4 is incorporated herein.

Item 8.

n/a

Item 9.

n/a

Item 10.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above  were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

 

 

 

EXHIBIT INDEX

 

EXHIBIT A

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Crinetics Pharmaceuticals, Inc. dated as of February 14, 2023 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.